12-week, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. - A0221008

Pfizer0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•- Overactive bladder symptoms for more than 3 months prior to screening/enrolment visit (visit 1)
•- Reported at least an everage of 1 UUI episode per 24 hours in the 3-day micturition diary prior to the randomization/baseline visit (visit 2)

•-Any condition that would contraindicate their usage of fesoterodine including: hypersensitivity to the active substance or to peanut or soya or any of the excipients, urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe hepatic impairment, severe ulcerative colitis, and toxic megacolon.
•-Clinically significant hepatic or renal disease, and/or with a screening test of AST,ALT, ALP, urea nitrogen, or creatinine greater than 1.5 times of the upper limit of normal range (ULN)
•See for more exclusion criteria p.19-21

发起方